Inhalation Anesthesia Market share to grow at 3.5% CAGR from 2017 to 2024: Global Market Insights Inc. In what may be construed as a breakthrough in inhalation anesthesia market, Baxter International Incorporation, a medical products manufacturer, has collaborated with Dorizoe Lifesciences Limited, a CRO firm, to develop over twenty generic injectable high-quality products comprising oncolytics, cardiovascular medicines, and antiinfectives. Baxter had already made it to the headlines earlier this year for its acquisition of Claris injectables limited, a key player across inhalation anesthesia industry, in a bid to expand its geographical presence. Apparently, Claris’ inclusion in its acquisition fold would help the firm consolidate their portfolio of anesthesia and analgesics drug products. Baxter’s unpretentious but powerful penetration in inhalation anesthesia industry underlines its commitment toward the medical and pharma verticals. Driven by the commendable efforts of medical companies and the robust prevalence of chronic ailments leading to the subsequent demand for anesthetics, inhalation anesthesia market size was pegged at USD 1,285.8 million in 2016.
The product landscape of inhalation anesthesia market comprises isoflurane, sevoflurane, and desflurane – essential anesthetics used during crucial surgeries. Sevoflurane among these, is renown to have contributed significantly towards inhalation anesthesia industry revenue in 2016. Subject to favorable product features such as low flammability and intrinsic stability, sevoflurane inhalation anesthesia market share is set to witness a commendable expansion over the next few years. Its counterpart – isoflurane is mostly preferred in neurosurgeries due to its ability to potentiate muscle relaxant activity and assist the expansion of systemic vessels. Considering the rising prevalence of chronic diseases such as cancer across the U.S., in tandem with the high-grade healthcare infrastructure and medical care expenditure of the country, it comes as no surprise that the United States is one of most remunerative avenues for inhalation anesthesia market. Estimates claim that the U.S. dominated the regional market share in 2016, driven by the surging product deployment in plastic surgeries and the growing prevalence of chronic lower respiratory ailments.
1|Page